<DOC>
	<DOCNO>NCT02385227</DOCNO>
	<brief_summary>This randomize , open-label , forced-switch , parallel , proof-of-concept study ass exposure biomarkers tobacco exposure follow short-term ad lib use three blu e-cigarette product . The primary objective study : 1 . Compare change select urine blood biomarkers tobacco exposure within cohort follow 5-day forced-switch usual brand conventional combustible cigarette exclusive use blu e-cigarettes , dual use blu e cigarettes subject 's usual brand combustible cigarette , smoke cessation . 2 . Compare change select urine blood biomarkers tobacco exposure among cohort follow 5-day forced-switch usual brand conventional combustible cigarette exclusive use blu e cigarette , dual use blu e-cigarette subject 's usual brand combustible cigarette , smoke cessation . The secondary objective study : 1 . Compare change select physiological endpoint affect tobacco exposure within cohort 5-day forced-switch usual brand conventional combustible cigarette exclusive use blu e cigarette , dual use blu e cigarettes subject 's usual brand combustible cigarette , smoke cessation . 2 . Compare change select physiological endpoint affect tobacco exposure among cohort follow forced-switch exclusive use blu e cigarette , dual use blu e-cigarette subject 's usual brand combustible cigarette , smoke cessation . 3 . Determine daily nicotine consumption blu e-cigarettes follow exclusive use blu e cigarette dual use blu e-cigarettes subject 's usual brand combustible cigarette 5-day period . 4 . Assess effectiveness exclusive use blu e-cigarettes dual use blu e-cigarettes subject 's usual brand combustible cigarette reduce urge smoke . 5 . Assess subject opinion various characteristic blu e-cigarettes . 6 . Assess safety tolerability short-term use blu e-cigarettes .</brief_summary>
	<brief_title>Characterization Biomarkers Tobacco Exposure , Urge-to-Smoke Following Exclusive Dual Ad Lib Use Electronic Cigarettes</brief_title>
	<detailed_description>Subjects check clinic Day -2 continue smoke usual brand cigarette ad lib even Day -1 upon request clinic staff . Baseline assessment make morning Day -1 morning Day 1 prior start randomize product use . On morning Day 1 , subject randomize one study arm note post-baseline assessment make morning Day 6 . With limited exception , product use ad lib 07:30 23:00 Days -2 5 . Smoking cigarette use e-cigarette product limit separate section clinic minimize chance illicit product use cross-contamination . Subjects randomize cessation arm house separate section clinic randomization . From Day 1 end study subject randomize e-cigarette cohort allow carry assign product throughout day use product ad lib within identified section clinic . Subjects randomize dual-use cohort allow smoke 50 % number cigarette per day report Screening . Cigarettes provide subject upon request study staff . Daily product use blu e-cigarettes usual brand cigarette assess Days -1 Day 5 . Each blu e‑cigarette weigh prior dispense follow return product estimate amount nicotine deliver blu e-cigarette calculate multiply weight difference ( mg ) 2.4 % . Urine biomarkers exposure effect assess 24-hour urine collection morning Day -1 morning Day 1 morning Day 5 morning Day 6 . Urine biomarkers exposure include NNAL , nicotine equivalent ( nic + 5 ) , 3-HPMA , CEMA , 1-OHP , NNN , MHBMA , S-PMA . The urine biomarker effect include F2-isoprostane ( 8-iso-PGF2 Type III ) . Biomarker concentration adjust urine creatinine concentration . Blood biomarkers exposure include COHb , nicotine , cotinine , trans-3'hydroxycotinine . Samples collect Days -1 , 1 , 3 , 5 morning prior start product administration evening . Other physiologic endpoint include spirometry ( FVC FEV1 , assess afternoon Day -1 Day 5 , exhale CO NO measurement ( assessed afternoon Days ‑1 , 1 , 3 , 5 ) , blood pressure pulse rate ( assessed Days -1 5 morning prior start product administration even ) . Questionnaires administer include Fagerström Test Nicotine Dependence Brief Wisconsin Inventory Smoking Dependence Motives ( Day -1 ) , smoke urge ( Days -1 5 morning prior start product administration even ) , Modified Cigarette Evaluation Scale ( even Day 5 , administer subject cessation arm ) . Safety evaluation include physical examination , vital sign , ECGs , clinical laboratory assessment ( clinical chemistry , hematology , urinalysis , serology ) , urine drug alcohol screen , urine cotinine exhale CO screen , pregnancy test ( female ) . Adverse event spontaneously report subject observe Investigator study personnel monitor time Check-in End-of-Study ( Early Termination ) . Any concomitant medication take 30 day prior Check-in End-of-Study ( Early Termination ) record .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Healthy adult male female smoker , 21 65 year age , inclusive , Screening . 2 . Combustible cigarette smoker least 12 month prior Checkin . Brief period nonsmoking 90 14 day prior Checkin ( e.g. , ~7 consecutive day due illness , try quit , participation study smoking prohibit ) permit discretion Investigator . 3 . Currently smoke average 10 king size ( ~83 85 mm ) 100 ( ~98 100 mm ) manufacture combustible cigarette per day ( brand style ) . 4 . Consistent use single brand style 14 day prior Checkin . 5 . Positive urine cotinine Screening ( ≥ 500 ng/mL ) . 6 . Exhaled CO &gt; 12 ppm Screening . 7 . Female subject nonchildbearing potential childbearing potential eligible . Examples acceptable form contraception include , limited , follow . Surgeries : Hysterectomy least 6 month prior product administration ; Oophorectomy least 6 month prior product administration ; Tubal ligation least 6 month prior product administration Transcervical sterilization least 6 month prior product administration Hormonal birth control least 3 month prior product administration Nonhormonal intrauterine device least 3 month prior product administration Double barrier method ( e.g. , condom spermicide ) least 14 day prior product administration Abstinence least 14 day prior product administration Vasectomized partner acceptable birth control females provide surgery perform least 6 month prior product administration Postmenopausal least 1 year prior product administration confirm follicle stimulate hormone ( FSH ) test Screening . 8 . Understands study procedure provide voluntary consent participate study document sign ICF . 9 . Willing comply study requirement , include potential use study product smoke cessation study . 1 . History presence clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , urologic , pulmonary ( especially bronchospastic disease ) , immunologic , psychiatric , cardiovascular disease , condition , opinion Investigator , would jeopardize safety subject impact validity study result . 2 . Clinically significant abnormal finding physical examination , medical history , ECG , clinical laboratory result Screening Checkin , opinion Investigator . 3 . Positive test HIV , HbsAg , HCV . 4 . An acute illness ( e.g. , upper respiratory infection , viral infection ) require treatment within 2 week prior Checkin . 5 . Fever ( &gt; 100.2F ) Screening Checkin . 6 . Systolic blood pressure &gt; 150 mmHg , diastolic blood pressure &gt; 95 mmHg , pulse rate &gt; 99 bpm Screening . 7 . BMI &lt; 18 kg/m2 &gt; 40 kg/m2 Screening . 8 . Female subject pregnant , lactating , intend become pregnant Screening completion study . 9 . Use prescription antidiabetic medication and/or insulin therapy within 12 month Checkin . 10 . Use medication food know suspected interact cytochrome P450 2A6 ( include , limited , amiodarone , amlodipine , amobarbital , buprenorphine , clofibrate , clotrimazole , desipramine , disullfiram , entacapone , fenofibrate , isoniazid , grapefruit , ketoconazole , letrozole , methimazole , methoxsalen , metyrapone , miconazole , modafinil , orphenadrine , pentobarbital , phenobarbital , pilocarpine , primidone , propoxyphene , quinidine , rifampicin , rifampin , secobarbital , selegiline , sulconazole , tioconazole , tranylcypromine , ) within 14 day five halflives drug , whichever longer , prior Checkin . 11 . Use inhaler treat medical condition within 3 month prior Checkin throughout study . 12 . Positive urine screen alcohol drug abuse Screening Checkin . 13 . History drug alcohol abuse within 24 month prior Checkin . 14 . Plasma donation within 7 day prior Checkin . 15 . Donation blood blood product , significant blood loss , receive whole blood blood product transfusion within 56 day prior Checkin . 16 . Participation previous clinical study investigational drug , biologic , medical device , tobacco product within 28 day prior Checkin . 17 . Use tobacco nicotinecontaining product ( e.g. , rollyourown cigarette , bidis , snuff , snus , tablet , inhaler , pipe , cigar , chew tobacco , nicotine replacement therapy [ e.g. , gum , patch , lozenge , nasal spray , inhaler ] ) manufacture cigarette ecigarettes within 28 day prior Checkin . 18 . Use prescription smoke cessation treatment , include , limited , varenicline ( Chantix ) buproprion ( Zyban ) within 3 month prior Checkin . 19 . Known hypersensitivity study product , glycerol , propylene glycol . 20 . Selfreported puffer ( i.e. , smoker draw smoke cigarette mouth throat inhale ) . 21 . Subject firstdegree relative ( i.e. , parent , sibling , child ) current former employee tobacco industry name party class representative litigation tobacco industry .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>